🇺🇸 FDA
Pipeline program

TP-05 (lotilaner) Low Dose

TRS-018

Phase 2 small_molecule active

Quick answer

TP-05 (lotilaner) Low Dose for Lyme Disease is a Phase 2 program (small_molecule) at Tarsus Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Tarsus Pharmaceuticals
Indication
Lyme Disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials